Crescent Biopharma, Inc. (CBIO) - Net Assets
Based on the latest financial reports, Crescent Biopharma, Inc. (CBIO) has net assets worth $163.25 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($182.76 Million) and total liabilities ($19.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See CBIO net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $163.25 Million |
| % of Total Assets | 89.33% |
| Annual Growth Rate | 25.48% |
| 5-Year Change | 148.78% |
| 10-Year Change | 475.09% |
| Growth Volatility | 447.84 |
Crescent Biopharma, Inc. - Net Assets Trend (2011–2025)
This chart illustrates how Crescent Biopharma, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Crescent Biopharma, Inc..
Annual Net Assets for Crescent Biopharma, Inc. (2011–2025)
The table below shows the annual net assets of Crescent Biopharma, Inc. from 2011 to 2025. Also explore Crescent Biopharma, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $203.01 Million | +1411.53% |
| 2024-12-31 | $-15.48 Million | -140.29% |
| 2023-12-31 | $38.41 Million | -10.52% |
| 2022-12-31 | $42.93 Million | -47.39% |
| 2021-12-31 | $81.60 Million | -36.36% |
| 2020-12-31 | $128.22 Million | -16.85% |
| 2019-12-31 | $154.20 Million | -24.95% |
| 2018-12-31 | $205.46 Million | +71.65% |
| 2017-12-31 | $119.70 Million | +239.09% |
| 2016-12-31 | $35.30 Million | -12.78% |
| 2015-12-31 | $40.47 Million | -20.34% |
| 2014-12-31 | $50.80 Million | +1647.37% |
| 2013-12-31 | $2.91 Million | -76.79% |
| 2012-12-31 | $12.53 Million | +48.14% |
| 2011-12-31 | $8.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Crescent Biopharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11548315500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.01% |
| Other Components | $374.79 Million | 184.62% |
| Total Equity | $203.01 Million | 100.00% |
Crescent Biopharma, Inc. Competitors by Market Cap
The table below lists competitors of Crescent Biopharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Forge Global Holdings Inc
NYSE:FRGE
|
$623.01 Million |
|
Naphtha
TA:NFTA
|
$623.09 Million |
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
$623.20 Million |
|
Olvi Oyj A
HE:OLVAS
|
$623.23 Million |
|
T'way Air Co Ltd
KO:091810
|
$622.83 Million |
|
Apple Flavor&Fragrance Grp
SHG:603020
|
$622.78 Million |
|
Ridgepost Capital, Inc
NYSE:RPC
|
$622.63 Million |
|
Guizhou Taiyong Changzheng Technology Co Ltd Class A
SHE:002927
|
$622.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Crescent Biopharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -15,479,000 to 203,012,000, a change of 218,491,000.
- Net loss of 153,942,000 reduced equity.
- Share repurchases of 177,000 reduced equity.
- New share issuances of 321,887,000 increased equity.
- Other factors increased equity by 50,723,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-153.94 Million | -75.83% |
| Share Repurchases | $177.00K | -0.09% |
| Share Issuances | $321.89 Million | +158.56% |
| Other Changes | $50.72 Million | +24.99% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Crescent Biopharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.37x to 0.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $45.03 | $16.77 | x |
| 2012-12-31 | $1047.35 | $16.77 | x |
| 2013-12-31 | $54.64 | $16.77 | x |
| 2014-12-31 | $275.32 | $16.77 | x |
| 2015-12-31 | $212.89 | $16.77 | x |
| 2016-12-31 | $166.07 | $16.77 | x |
| 2017-12-31 | $407.21 | $16.77 | x |
| 2018-12-31 | $500.59 | $16.77 | x |
| 2019-12-31 | $356.49 | $16.77 | x |
| 2020-12-31 | $280.44 | $16.77 | x |
| 2021-12-31 | $158.60 | $16.77 | x |
| 2022-12-31 | $81.72 | $16.77 | x |
| 2023-12-31 | $60.65 | $16.77 | x |
| 2024-12-31 | $-20.17 | $16.77 | x |
| 2025-12-31 | $19.49 | $16.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Crescent Biopharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1419.61%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.18x
- Recent ROE (-75.83%) is below the historical average (-69.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -72.29% | -160.29% | 0.13x | 3.42x | $-6.96 Million |
| 2012 | 29.18% | 23.96% | 0.83x | 1.47x | $2.40 Million |
| 2013 | -364.78% | -265.63% | 0.76x | 1.82x | $-10.90 Million |
| 2014 | -21.89% | -74.01% | 0.26x | 1.13x | $-16.20 Million |
| 2015 | -31.55% | -63.62% | 0.41x | 1.20x | $-16.82 Million |
| 2016 | -90.11% | -171945.07% | 0.00x | 1.20x | $-35.34 Million |
| 2017 | -27.80% | 0.00% | 0.00x | 1.07x | $-45.25 Million |
| 2018 | -23.50% | 0.00% | 0.00x | 1.05x | $-68.82 Million |
| 2019 | -35.09% | 0.00% | 0.00x | 1.09x | $-69.54 Million |
| 2020 | -39.80% | -502.09% | 0.07x | 1.11x | $-63.85 Million |
| 2021 | -77.73% | -5468.98% | 0.01x | 1.16x | $-71.59 Million |
| 2022 | -108.76% | -62251.74% | 0.00x | 1.21x | $-50.98 Million |
| 2023 | -96.06% | -368994.20% | 0.00x | 1.18x | $-40.74 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.98 Million |
| 2025 | -75.83% | -1419.61% | 0.05x | 1.18x | $-174.24 Million |
Industry Comparison
This section compares Crescent Biopharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $163.25 Million | -72.29% | 0.12x | $622.90 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more